Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia

Vera H. Price, Janet L. Roberts, Maria K Hordinsky, Elise A. Olsen, Ronald Savin, Wilma Bergfeld, Virginia Fiedler, Anne Lucky, David A. Whiting, Frances Pappas, Jennifer Culbertson, Paul Kotey, Alan Meehan, Joanne Waldstreicher

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Background: Finasteride, an inhibitor of type 2 5α-reductase, decreases serum and scalp dihydrotestosterone (DHT) by inhibiting conversion of testosterone to DHT and has been shown to be effective in men with androgenetic alopecia (AGA). The effects of finasteride in women with AGA have not been evaluated. Objective: The purpose of this study was to evaluate the efficacy of finasteride in postmenopausal women with AGA. Methods: In this 1-year, double-blind, placebo-controlled, randomized, multicenter trial, 137 post-menopausal women (41-60 years of age) with AGA received finasteride 1 mg/day or placebo. Efficacy was evaluated by scalp hair counts, patient and investigator assessments, assessment of global photographs by a blinded expert panel, and histologic analysis of scalp biopsy specimens. Results: After 1 year of therapy, there was no significant difference in the change in hair count between the finasteride and placebo groups. Both treatment groups had significant decreases in hair count in the frontal/parietal (anterior/mid) scalp during the 1-year study period. Similarly, patient, investigator, and photographic assessments as well as scalp biopsy analysis did not demonstrate any improvement in slowing hair thinning, increasing hair growth, or improving the appearance of the hair in finasteride-treated subjects compared with the placebo group. Finasteride was generally well tolerated. Conclusion: In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning.

Original languageEnglish (US)
Pages (from-to)768-776
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume43
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Finasteride
Alopecia
Hair
Scalp
Placebos
Dihydrotestosterone
Research Personnel
Biopsy
Growth
Multicenter Studies
Testosterone
Oxidoreductases

Cite this

Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. / Price, Vera H.; Roberts, Janet L.; Hordinsky, Maria K; Olsen, Elise A.; Savin, Ronald; Bergfeld, Wilma; Fiedler, Virginia; Lucky, Anne; Whiting, David A.; Pappas, Frances; Culbertson, Jennifer; Kotey, Paul; Meehan, Alan; Waldstreicher, Joanne.

In: Journal of the American Academy of Dermatology, Vol. 43, No. 5, 01.01.2000, p. 768-776.

Research output: Contribution to journalArticle

Price, VH, Roberts, JL, Hordinsky, MK, Olsen, EA, Savin, R, Bergfeld, W, Fiedler, V, Lucky, A, Whiting, DA, Pappas, F, Culbertson, J, Kotey, P, Meehan, A & Waldstreicher, J 2000, 'Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia', Journal of the American Academy of Dermatology, vol. 43, no. 5, pp. 768-776. https://doi.org/10.1067/mjd.2000.107953
Price, Vera H. ; Roberts, Janet L. ; Hordinsky, Maria K ; Olsen, Elise A. ; Savin, Ronald ; Bergfeld, Wilma ; Fiedler, Virginia ; Lucky, Anne ; Whiting, David A. ; Pappas, Frances ; Culbertson, Jennifer ; Kotey, Paul ; Meehan, Alan ; Waldstreicher, Joanne. / Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. In: Journal of the American Academy of Dermatology. 2000 ; Vol. 43, No. 5. pp. 768-776.
@article{98cc67574bf34b9c90a1b2a1e9d6345b,
title = "Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia",
abstract = "Background: Finasteride, an inhibitor of type 2 5α-reductase, decreases serum and scalp dihydrotestosterone (DHT) by inhibiting conversion of testosterone to DHT and has been shown to be effective in men with androgenetic alopecia (AGA). The effects of finasteride in women with AGA have not been evaluated. Objective: The purpose of this study was to evaluate the efficacy of finasteride in postmenopausal women with AGA. Methods: In this 1-year, double-blind, placebo-controlled, randomized, multicenter trial, 137 post-menopausal women (41-60 years of age) with AGA received finasteride 1 mg/day or placebo. Efficacy was evaluated by scalp hair counts, patient and investigator assessments, assessment of global photographs by a blinded expert panel, and histologic analysis of scalp biopsy specimens. Results: After 1 year of therapy, there was no significant difference in the change in hair count between the finasteride and placebo groups. Both treatment groups had significant decreases in hair count in the frontal/parietal (anterior/mid) scalp during the 1-year study period. Similarly, patient, investigator, and photographic assessments as well as scalp biopsy analysis did not demonstrate any improvement in slowing hair thinning, increasing hair growth, or improving the appearance of the hair in finasteride-treated subjects compared with the placebo group. Finasteride was generally well tolerated. Conclusion: In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning.",
author = "Price, {Vera H.} and Roberts, {Janet L.} and Hordinsky, {Maria K} and Olsen, {Elise A.} and Ronald Savin and Wilma Bergfeld and Virginia Fiedler and Anne Lucky and Whiting, {David A.} and Frances Pappas and Jennifer Culbertson and Paul Kotey and Alan Meehan and Joanne Waldstreicher",
year = "2000",
month = "1",
day = "1",
doi = "10.1067/mjd.2000.107953",
language = "English (US)",
volume = "43",
pages = "768--776",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia

AU - Price, Vera H.

AU - Roberts, Janet L.

AU - Hordinsky, Maria K

AU - Olsen, Elise A.

AU - Savin, Ronald

AU - Bergfeld, Wilma

AU - Fiedler, Virginia

AU - Lucky, Anne

AU - Whiting, David A.

AU - Pappas, Frances

AU - Culbertson, Jennifer

AU - Kotey, Paul

AU - Meehan, Alan

AU - Waldstreicher, Joanne

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Finasteride, an inhibitor of type 2 5α-reductase, decreases serum and scalp dihydrotestosterone (DHT) by inhibiting conversion of testosterone to DHT and has been shown to be effective in men with androgenetic alopecia (AGA). The effects of finasteride in women with AGA have not been evaluated. Objective: The purpose of this study was to evaluate the efficacy of finasteride in postmenopausal women with AGA. Methods: In this 1-year, double-blind, placebo-controlled, randomized, multicenter trial, 137 post-menopausal women (41-60 years of age) with AGA received finasteride 1 mg/day or placebo. Efficacy was evaluated by scalp hair counts, patient and investigator assessments, assessment of global photographs by a blinded expert panel, and histologic analysis of scalp biopsy specimens. Results: After 1 year of therapy, there was no significant difference in the change in hair count between the finasteride and placebo groups. Both treatment groups had significant decreases in hair count in the frontal/parietal (anterior/mid) scalp during the 1-year study period. Similarly, patient, investigator, and photographic assessments as well as scalp biopsy analysis did not demonstrate any improvement in slowing hair thinning, increasing hair growth, or improving the appearance of the hair in finasteride-treated subjects compared with the placebo group. Finasteride was generally well tolerated. Conclusion: In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning.

AB - Background: Finasteride, an inhibitor of type 2 5α-reductase, decreases serum and scalp dihydrotestosterone (DHT) by inhibiting conversion of testosterone to DHT and has been shown to be effective in men with androgenetic alopecia (AGA). The effects of finasteride in women with AGA have not been evaluated. Objective: The purpose of this study was to evaluate the efficacy of finasteride in postmenopausal women with AGA. Methods: In this 1-year, double-blind, placebo-controlled, randomized, multicenter trial, 137 post-menopausal women (41-60 years of age) with AGA received finasteride 1 mg/day or placebo. Efficacy was evaluated by scalp hair counts, patient and investigator assessments, assessment of global photographs by a blinded expert panel, and histologic analysis of scalp biopsy specimens. Results: After 1 year of therapy, there was no significant difference in the change in hair count between the finasteride and placebo groups. Both treatment groups had significant decreases in hair count in the frontal/parietal (anterior/mid) scalp during the 1-year study period. Similarly, patient, investigator, and photographic assessments as well as scalp biopsy analysis did not demonstrate any improvement in slowing hair thinning, increasing hair growth, or improving the appearance of the hair in finasteride-treated subjects compared with the placebo group. Finasteride was generally well tolerated. Conclusion: In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning.

UR - http://www.scopus.com/inward/record.url?scp=0033752238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033752238&partnerID=8YFLogxK

U2 - 10.1067/mjd.2000.107953

DO - 10.1067/mjd.2000.107953

M3 - Article

VL - 43

SP - 768

EP - 776

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5

ER -